Research led by Professor Michele Hu and Dr Sanjay Manohar at Oxford University, and utilising data from the PSPA funded PROSPECT-M-UK study has helped to establish a method for improving diagnosis.
The study which analysed data from 1,100 people has helped to ascertain distinct cognitive profiles and neuro-psychiatric features affecting both motor and cognitive function. Using this data the team has developed a classifier which can be used to diagnose PSP & CBD, distinguishing them from other conditions such as Parkinson’s or Multiple System Atrophy.
Using simple bedside tests such as The Montreal Cognitive Assessment test, the team found PSP was characterised by significant planning and decision-making impairments. Whereas CBD was characterised by visuospatial difficulties.
With PSP & CBD, a correlation was found between motor function decline and poorer cognition, both progressing at a similar rate. The study also found that cognition decline was the biggest factor contributing to difficulties in performing daily activities.
Based on these findings, the researchers developed a classifier aimed at improving the accuracy of diagnosing conditions like PSP & CBD during life. Ongoing research is needed however, to further validate and improve diagnostic tools for these challenging conditions.
Read more about the study here. Learn how we want to unlock quick and accurate diagnosis, immediate treatment and consistent care by investing more funds into research as part of our Understood Appeal.


